Table of Contents
- Trial overview
- Study design and treatment groups
- Who could join the study
- What was measured
- Trial status and size
Trial overview
The available trial data show one Phase 2 study of Ly4100511 in adults with moderate-to-severe plaque psoriasis.[1] The study was designed to compare several dose regimens of Ly4100511 with placebo in people who had this skin condition.[1]
Study design and treatment groups
This was an interventional trial, which means researchers assigned participants to study treatment groups rather than just observing them.[1] The trial included placebo tablets and Ly4100511 tablets taken by mouth, and the placebo was made to look the same as the active tablets.[1] The study was also described as a dose-ranging study, meaning it tested multiple dose regimens to compare their effects.[1]
Who could join the study
The study population was adult participants with moderate-to-severe plaque psoriasis.[1] No other participant groups were listed in the trial data, so the main target population was adults with this form of psoriasis.[1]
What was measured
The main endpoint was the proportion of participants achieving PASI 75 at Week 12.[1] PASI 75 means a 75% improvement in the psoriasis severity score, so this endpoint checks how many people had a strong improvement after 12 weeks.[1] The study summary says the goal was to compare the efficacy of multiple dose regimens of Ly4100511 versus placebo.[1]
Trial status and size
The trial is listed as completed, which means the study has finished and the data have been collected.[1] It enrolled 191 participants.[1]
